L300 Foot Drop System Can Help Children with Cerebral Palsy, Stroke or Traumatic Brain Injury Regain Mobility and Lead More Independent Lives VALENCIA, Calif.--(BUSINESS WIRE)--Bioness Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its L300® Foot Drop System to pediatric patients and their caregivers. This is the first FDA cleared neurostimulation device of this kind for use with children. The L300 is a neuromodulation technology designed to treat foot drop, a condition which causes walking difficulty in adults and pediatrics with upper motor neuron pathologies. Bioness will be showcasing the system and its use in pediatrics...
0 Responses to Bioness Receives First FDA Clearance of Neurostimulation System for Children Suffering from Foot Drop